India comes second in the world when it comes to diabetic population. There are over 101 million in India that are diabetic. Urbanization, sedentary lifestyles and dietary changes are are one of the major reasons for type 2 diabetes in India.
As the disease burden intensifies, the demand for anti-diabetic drugs and modern care solutions has grown significantly Diabetes mellitus is a chronic metabolic disorder caused by either inadequate insulin production or the body’s inability to use insulin effectively—leading to elevated blood glucose levels.
This results in a strong need for anti-diabetic drugs in India. Diabetes mellitus which is a chronic metabolic disorder is caused by either inadequate insulin production in the body, or the inability of our body to use insulin effectively, and the result is: high blood sugar levels. Indians are 8.3% of world’s diabetic share.
Quick Overview of Anti-Diabetic Drugs in India
In India, the market value for anti-diabetic drugs accounts to around $ 2.74 billion in 2025 and according to Statista, this number is expected to reach around $3,91 billion by 2030.
Key reasons for this staggering are:
- Increasing diabetic patients in urban and semi-urban regions.
- Rising awareness among the general public, and early diagnosis.
- Drug delivery systems and formulations upgrades.
- Advances in drug delivery systems and formulations.
Types of Anti-Diabetic Drugs in India
India’s pharmaceutical industry offers a comprehensive range of diabetes treatment options:
In India, there is an array of diabetes treatment options. The 3 treatment methods available in India pharmaceutical industry are:
1. Oral Anti-Diabetic Drugs
Drug Class
|
Examples
|
Mechanism
|
|
Biguanides
|
Metformin
|
Reduces glucose production in the liver.
|
|
Sulfonylureas
|
Glimepiride, Gliclazide
|
Stimulates insulin secretion.
|
|
DPP-4 Inhibitors
|
Sitagliptin, Vildagliptin
|
Enhances incretin hormone levels.
|
|
SGLT2 Inhibitors
|
Empagliflozin, Dapagliflozin
|
Promotes urinary glucose excretion.
|
- Biguanides: Metformin:Reduces glucose production in the liver.
- Sulfonylureas:Glimepiride, Gliclazide:Stimulates insulin secretion.
- DPP-4 Inhibitors:Sitagliptin, Vildagliptin:Enhances incretin hormone levels.
- SGLT2 Inhibitors:Empagliflozin, Dapagliflozin:Promotes urinary glucose excretion.
2. Insulin Therapies
- Rapid-acting insulin (e.g., Lispro, Aspart): This is used before meals.
- Long-acting insulin (e.g., Glargine, Detemir): Such types of medications helps in maintaining baseline control.
- Premixed insulin: This combines rapid and long-acting insulin for convenience.
3. Non-Insulin Injectables
- GLP-1 Receptor Agonists (e.g., Liraglutide, Semaglutide): Stimulate insulin secretion and reduce appetite.
Key Challenges in Diabetes Management in India
India is one of the nations that is making significant innovations in drug formulations and manufacturing, increasing access to good and advance healthcare services, and strict adherence to guidelines. But still a few challenges are still prevailing in managing diabetes in India. These challenges are as follow:
- Limited availability of affordable medicines in rural India.
- Inadequate diabetes education and awareness.
- High out-of-pocket expenditure for long-term treatment.
- Poor patient adherence to prescribed regimens.
Key Players working on Anti-diabetic Drugs in India
- Novo Nordisk - Expanding injectable therapies and GLP-1 agonists.
- Eli Lilly & Co. - Affordable insulin and R&D collaborations.
- Sanofi - Dominates with pre-filled pens and extended insulin options.
These companies hold over 50% of the global diabetes drug market, and are strengthening their presence in developing markets like India through partnerships and pricing strategies.
Notable Industry Developments (2022–2025)
- Sanofi India: Approved to launch Soliqua (GLP-1 + insulin) in pre-filled pen format.
- Glenmark: Introduced Zita-Pio Met, a cost-effective oral option for Type 2 diabetes.
- Akums Drugs: Launched Lobeglitazone, a new insulin sensitizer.
- IIT Bhilai & Shiv Nadar University: Developed "Smart Insulin" with extended release for up to 48 hours.
- Biocon: Received approval in May 2025 for Liraglutide, a GLP-1 analog.
The Future of Anti-Diabetic Drugs in India
The market of ant-diabetic drugs in India is expanding rapidly. Innovation, digital expansion, and lenient policies have made this process even faster. Here are 3 key changes, India’s anti-diabetic industry is working on:
1. Rapid Innovation
One of the biggest changes that we are about to face in the market is not going to be a brand new drug, but innovative and scientific upgrades in the existing treatment methods. Here’s how:
- Next-Gen GLP-1 Agonists: Unlike regular glucose controllers, these will also aid the patient in weight loss as well. As obesity is just another aspect of diabetes, solving both of them together will lead a significant reduction in complications.
- Dual-Action Therapies: The combination of GLP-1 agonists and SGLT2 inhibitors will lead to better glycemic control, reduced cardiovascular risks, and weight reduction. A lot of Indian companies are already exploring FDCs (Fixed Dose Combinations).
- Oral Insulin Formulations: Oral insulin are currently under development, but if successful, they can lead to a serious revolution in the market.
- Gene Therapy & Stem Cells: This method is under trials, but it can either regenerate the beta cells or lead to correct insulin gene expression.
2. Artificial Intelligence in diagnostics and checkups
AI is one of the key contributors in the batter against diabetes in India:
- AI-Powered Diagnostics: The speed at which AI is growing can significantly help in early detection of pre-diabetes by just using basic health data. This process will be faster than lab tests and cheaper as well. Startups like SigTuple and Qure.ai are already deploying AI in diagnostics across India.
- Wearable Glucose Monitors: CGMs are wearable devices that can track your sugar levels all day, no need to use pricks.
- Telemedicine + Remote Coaching: After Covid-19, the rise of telemedicines can help patients connect with their endocrinologists directly from the comfort of their homes using softwares like Zoom or WhatsApp.
- Apps Like BeatO and HealthifyMe: These mobile applications are not just handy, but also highly intuitive. These can use AI to give you feedback, and there will be real coaches as well to give you accurate and right information. Plus, there are a few apps that can provide real-time corrections in your diet, right after your meals.
3. Policy Lineancy
The Indian government is no longer passive. Diabetes is a national priority.
- NDCP (National Diabetes Control Program): This program is nation-wide implemented. The primary focuse is on early screening, community health worker training, and school-based education. This helps greatly since early-stage intervention is much cheaper, effective and scalable.
- Price Regulation of Essential Drugs: NPPA, leads to essential drugs being made more accessible, and cheaper. This results in better outcomes.
- Public-Private Partnerships (PPPs): Partnerships between NGOs, tech platforms, and pharma players improves the delivery models, and due to this, affordable CGMs are now available in health clinics.
Using Chemxpert Database to track Anti-diabetic drugs in India and Globe
Chemxpert database is one of the best pharmaceutical database provider in the world. Where you get everything from chemical research data, chemical engineering, data on research and development and much more under one roof. Here’s how Chemxpert database helps:
- Comprehensive drug profiles – With chemxpert you get detailed information on the ingredients, formulations and therapeutic class of any drug.
- Approval status – Our latest and up-to-date information helps you track regulatory approvals not just in India but around the globe.
- Manufacturer insights – With detailed data on manufactures, you know every details of drug manufacturers such as their name, the drugs they make and their location
- Pricing and market trends – Stay updated with the dynamic prices of anti-diabetic drugs in India and the world.
- Safety and efficacy data – Chemxpert database helps you understand clinical performance at a glance.
Chemxpert database helps you stay ahead in the diabetes care market.
Conclusion
India’s diabetes epidemic demands multi-dimensional solutions, ranging from breakthrough drugs and AI-powered health platforms to inclusive healthcare policies.With strong market growth, increased R&D, and a shift toward personalized medicine, the future of anti-diabetic drugs in India is both promising and transformative.
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!
